Search results
Amgen’s Imdelltra BiTEs into SCLC treatment drought
Clinical Trials Arena· 1 day agoSimilarly, Keytruda's addition to SOC only marginally improved the objective response rate (ORR). Keytruda and Bristol Myers Squibb’s Opdivo (nivolumab)...
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Pharmaceutical Technology· 5 days agoThe IBD field is quite crowded, with AbbVie’s Humira (adalimumab) being the top earner. However,...
Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win
Clinical Trials Arena· 6 days agoThe updated study protocol swapped Bristol Myers Squibb’s Opdivo (nivolumab) with toripalimab in a...